Product Description
A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Bleomycin-sulfate)
Mechanisms of Action: DNA Synthesis Inhibition,Protein Synthesis Inhibitor
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Brazil | Chile | Colombia | Dominican Republic | Ecuador | France | Germany | Indonesia | Ireland | Italy | Malaysia | Malta | Mexico | Norway | Pakistan | Peru | Portugal | Russia | Spain | Taiwan | Turkey | United States | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: IIL INTERGRUPPO ITALIANO LINFOMI ONLUS
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, Czech Republic, Denmark, France, Hungary, Italy, Norway, Poland, Spain, United States
Active Clinical Trial Count: 3
Highest Development Phases
Phase 3: Hodgkin Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| cHOD17 | P2 |
Recruiting |
Hodgkin Lymphoma |
2027-01-01 |
|
| C25003 | P3 |
Active, not recruiting |
Hodgkin Lymphoma |
2026-01-20 |
|
| HD21 (advanced stage) | P3 |
Active, not recruiting |
Hodgkin Lymphoma |
2025-10-18 |